Frank Taffy, JD

Frank Taffy is a life sciences entrepreneur, executive, board member, and strategic advisor with over 25 years of experience, particularly in the areas of corporate and business development. Mr. Taffy currently serves as Chief Business Officer of Congruence Therapeutics, a Montreal-based, private biotechnology company harnessing the power of protein dynamics, biophysics, machine learning, and computational chemistry in drug discovery. During his tenure at Congruence, he led the consummation of multi-target research collaborations with large pharmaceutical companies and was instrumental in the Company’s fundraising efforts. Mr. Taffy also currently serves as a member of the Board of Directors of Emtora Biosciences and Helocyte. Mr. Taffy co-founded Helocyte, a clinical-stage biopharmaceutical company, during his role as Entrepreneur in Residence at Fortress Biotech and previously served as the company's President and CEO. Prior to joining Congruence, Mr. Taffy served as Senior Vice President, Head of Business Development and Board Representative at Schrödinger – a pioneer in physics-based chemical simulation for drug discovery. Mr. Taffy also previously held the positions of Head of Business Affairs at Forest Labs (now part of AbbVie) and Director of Corporate Development at Life Technologies (now part of Thermo Fisher Scientific), where he also held board positions on behalf of the company. He also previously served as Vice President and General Counsel of Paramount Biosciences LLC, a global healthcare investment firm, where he led the forma on and interim operation of multiple portfolio companies. Mr. Taffy started his career as Counsel for Intellectual Property at The Procter and Gamble Company. He holds a B.A. in biochemistry from the University of North Texas and a J.D. from Syracuse University College of Law.